Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2019

View Archived Issues

Novel optimized allosteric SHP2 inhibitors that modulate MAPK signaling

Curl therapeutic RNA up into ball

The many shapes of tauopathy

Cathepsin S has a pathogenic role in CF and smoke-induced COPD: a potential target for lung diseases

Novel small-molecule RXFP3/4 agonist increases food intake in vivo

FT-113 shows promising antitumor activity in preclinical models

NLRP3 antagonist IFM-2427 enters first-in-human trial

Propellon Therapeutics discovers WDR5/MLL1 interaction inhibitors

New Toll-like receptor 7 agonists identified at BioNTech

Bioardis patents fibroblast growth factor receptor 4 inhibitors

Phase III PATENCY-2 trial of vonapanitase does not meet its coprimary endpoints

New ALK gene translocation found in gynecologic clear-cell carcinoma

Velicept presents positive topline results from VEL-2002 study of solabegron

Promising preclinical and first-in-human data presented for PRI-002

VALZ-pilot as the first clinical study to evaluate antiviral valaciclovir for the treatment of AD

NIAID initiates phase I study of inactivated subunit H5N1 influenza vaccine

Researchers identify new mutations in uveal melanoma

Phase II study of Foxy-5 as neoadjuvant therapy in Wnt-5a low colon cancer

Cimzia becomes the first and only FDA-approved treatment for nonradiographic axial spondyloarthritis

Odonate Therapeutics initiates CONTESSA TRIO phase II study of tesetaxel

Gilead Sciences and Galapagos present updated results for phase III studies of filgotinib

Pannexin 1 channelopathy causes human oocyte death

Orchard Therapeutics presents new registrational data for OTL-200 in MLD

First patient dosed in ReCLAIM-2 phase II study of elamipretide in AMD

Positive expression results presented from the casimersen arm of the ESSENCE study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 9, 2025.
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...